{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:38:00Z","timestamp":1790429880151,"version":"4.1.0"},"reference-count":17,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":1507,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect. This case report is the first document attesting Ra223 deposit in osteolytic metastases opening new opportunity of therapeutic development for this radiopharmaceutical.<\/jats:p>","DOI":"10.4103\/wjnm.wjnm_22_17","type":"journal-article","created":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T14:22:40Z","timestamp":1639923760000},"page":"116-119","source":"Crossref","is-referenced-by-count":3,"title":["Ra223 in bone metastases with osteolytic activity"],"prefix":"10.1055","volume":"17","author":[{"given":"Renato","family":"Costa","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cardile","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Murabito","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Tripoli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Verderame","sequence":"additional","affiliation":[{"name":"Department of Oncology, Villa Sofia-Cervello Hospital, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"key-10.4103\/1450-1147.229469-1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.6004\/jnccn.2016.0060","article-title":"NCCN guidelines insights: Prostate cancer early detection, Version 2.2016","author":"Carroll","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"key-10.4103\/1450-1147.229469-2","unstructured":"AIOM 2016 \u2013 Prostate Cancer Guidelines Downloadable. Available from: http:\/\/www.aiom.it\/C_Common\/Download.asp?file=\/$Site$\/files\/doc\/LG\/2016_LG_AIOM_Prostata.pdf. [Last accessed on 2017 Feb 28]."},{"key":"key-10.4103\/1450-1147.229469-3","first-page":"1659","article-title":"Radium-223 in prostate cancer","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1450-1147.229469-4","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00259-013-2427-6","article-title":"Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer","author":"Carrasquillo","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key-10.4103\/1450-1147.229469-5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/MNM.0b013e328353bb6e","article-title":"Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases","author":"Hindorf","year":"2012","journal-title":"Nucl Med Commun"},{"key":"key-10.4103\/1450-1147.229469-6","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1450-1147.229469-7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-2939-1","article-title":"A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease","author":"Coleman","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/1450-1147.229469-8","first-page":"2568031","article-title":"Radium-223 therapy for patients with metastatic castrate-resistant prostate cancer: An update on literature with case presentation","author":"Nguyen","year":"2016","journal-title":"Int J Mol Imaging"},{"key":"key-10.4103\/1450-1147.229469-9","doi-asserted-by":"crossref","unstructured":"Effect of radium-223 on breast cancer bone metastases in mice. Bonekey Rep 2013;2:457.","DOI":"10.1038\/bonekey.2013.191"},{"key":"key-10.4103\/1450-1147.229469-10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12149-016-1093-8","article-title":"Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases","author":"Yoshida","year":"2016","journal-title":"Ann Nucl Med"},{"key":"key-10.4103\/1450-1147.229469-11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1450-1147.229469-12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/fon.14.157","article-title":"Radium 223 dichloride: A multidisciplinary approach to metastatic castration-resistant prostate cancer","author":"Bors\u00f2","year":"2015","journal-title":"Future Oncol"},{"key":"key-10.4103\/1450-1147.229469-13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jnci\/djt116","article-title":"Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis","author":"Suominen","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1450-1147.229469-14","doi-asserted-by":"crossref","unstructured":"Abou DS, Ulmert D, Doucet M, Hobbs RF, Riddle RC, Thorek DL. Whole-body and microenvironmental localization of radium-223 in na\u00efve and mouse models of prostate cancer metastasis. J Natl Cancer Inst 2015;108. pii: Djv380.","DOI":"10.1093\/jnci\/djv380"},{"key":"key-10.4103\/1450-1147.229469-15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.4329\/wjr.v8.i10.816","article-title":"Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold","author":"Aprile","year":"2016","journal-title":"World J Radiol"},{"key":"key-10.4103\/1450-1147.229469-16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.cr.7290266","article-title":"Mechanisms of cancer metastasis to the bone","author":"Yin","year":"2005","journal-title":"Cell Res"},{"key":"key-10.4103\/1450-1147.229469-17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1758834015582178","article-title":"Bone-targeted agents in the treatment of lung cancer","author":"Silva","year":"2015","journal-title":"Ther Adv Med Oncol"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/wjnm.WJNM_22_17.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T22:44:15Z","timestamp":1652827455000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.4103\/wjnm.WJNM_22_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":17,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2018,4]]}},"URL":"https:\/\/doi.org\/10.4103\/wjnm.wjnm_22_17","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}